Preclinical Characterization and Phase I Study of an Anti–HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies
Filip Jankú(The University of Texas MD Anderson Cancer Center), Salvatore Siena(University of Milan)
Cited by 73
Related Papers
PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring <i>PIK3CA</i> Mutations
|Journal of Clinical Oncology|2012|451
Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
|Annals of Oncology|2019|300